<DOC>
	<DOCNO>NCT01249131</DOCNO>
	<brief_summary>This study open-label , randomize , 3-way , 6-sequence crossover study healthy participant determine relative bioavailability tablet formulation capsule formulation effect food relative bioavailability tablet formulation .</brief_summary>
	<brief_title>A Study Relative Bioavailability Food Effect Study Cobimetinib Healthy Participants</brief_title>
	<detailed_description />
	<criteria>Inclusion Criteria Within body mass index range 18.5 29.9 kilogram per meter square ( kg/m^2 ) In good health , determine clinically significant finding medical history , 12lead electrocardiogram ( ECG ) vital sign Clinical laboratory evaluation within reference range test laboratory Negative test select drug abuse Screening Checkin Negative hepatitis panel antihepatitis C virus negative human immunodeficiency virus ( HIV ) antibody screen Healthy male females nonchildbearing potential agree use effective contraception Exclusion Criteria Significant history clinical manifestation significant metabolic , allergic , dermatological , hepatic , renal , hematological , pulmonary , cardiovascular , gastrointestinal , neurological , psychiatric disorder History significant hypersensitivity , intolerance , allergy drug compound , food , substance History stomach intestinal surgery resection would potentially alter absorption and/or excretion orally administer drug except appendectomy , hernia repair , cholecystectomy allow History presence abnormal ECG History alcoholism drug addiction prior study start Use tobaccocontaining nicotinecontaining product prior study start Participation investigational study drug trial receipt investigational study drug occur within 28 day 5 halflives , whichever longer , prior study start Use prescription medications/products , include proton pump inhibitor , within 14 day prior study start Poor peripheral venous access Any acute chronic condition would limit participant 's ability complete and/or participate clinical study Female participant pregnant , lactating , breastfeed Predisposing factor retinal vein occlusion ( RVO )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>